Oura Ring Gen 4 sensor data, not clinical measurementsN=1 case study, not validated for clinical decisionsHEV diagnosed Mar 18; Day 223 post-ruxolitinibMore
Consumer wearable data can support exploratory review only. The HEV diagnosis, temporally confounded with treatment start, remains a material confounder.

Advanced Sleep Architecture Analysis

281 nights analyzed | 2026-01-08 to 2026-10-24 | Ruxolitinib start: 2026-03-16
Generated 2026-10-24 06:22 · Post-HSCT Patient · Data Jan 08, 2026 to Oct 24, 2026 · Day 223 post-treatment
Fragmentation
1.2trans/hr
0.0% above clinical threshold
Sleep Efficiency
Low
82.0%
66.2% of nights below 85%
Sleep Cycles
5.3/night
15.3% below 4 cycles
REM Latency
79.5min
12.1% above 120 min
HRV Coupling
Abnormal
Abnormal
Abnormal autonomic regulation
Ultradian Period
99.3min
Expected ~90 min (277 nights)
Clinical Interpretation
  • ABNORMAL: HRV is NOT higher during deep sleep than during light sleep. Normal parasympathetic dominance during deep sleep is absent - suggests autonomic dysfunction.
DASHBOARD

Sleep Architecture Analysis (9 panels)

Data window: January 08 to October 24, 2026 · Post-treatment: day 223 on ruxolitinib · Generated: 2026-10-24 06:22
Oura Ring Gen 4 consumer wearable data; N=1 exploratory case study; not a medical device. MIT License · © 2026 The Educational Equality Institute · Oura® is a registered trademark of Oura Health Oy.
Source code on GitHub · Built with Claude Code · TEEI Health Equity · Companion project: Genomics portal · How this was built · Every number, checked